Erythropoietin Drug Market Advancement Outlook | Market demand 2022
The worldwide demand for erythropoietin drugs also referred
as hematopoietin drugs is expected to remain strong in the forthcoming years.
Market Research Future (MRFR) reports that the global erythropoietin
drug market will post a above-average CAGR
between 2017 and 2023. The outlook remains positive for the global
erythropoietin drug market for the medium terms.
Erythropoietin drug are used for treating a wide-range of disorders,
which include AIDS, chronic renal diseases, anaemia, cancer, among others.
Increased prevalence of such diseases is boosting the sales of erythropoietin.
Over the years, tremendous investment has been made in research &
development programs focused on drug discovery, which has also influenced the
market growth to certain extent. Several new erythropoietin drug combinations
have come up in recent years. Introduction of new
drug combinations is allowing to drug makers to cater to wider pool of patients.
Rising awareness among patients and increased focus on
improving healthcare services in the developing countries is likely to open new
growth avenues for market players in near future. On the other hand, most of
the erythropoietin drug available are highly priced, which makes their
penetration in price sensitive markets difficult. This is viewed as a major
market constraint. Patient expiry and introduction of generic variants may
provide an impetus to drug penetration. Focus is also shifting on developing
alternative drugs formulations.
Segmental Overview
MRFR’s report includes a thorough segmental analysis of the
global erythropoietin drug market based on product type, application and end
user.
On the basis of product type, the market has been segmented
into second generation formulation, first generation formulation and biosimilars.
On the basis of application, the market has been segmented
into renal diseases, HIV, oncology and other.
On the basis of end user, the market has been segmented into
pharmacy and hospital.
Global Erythropoietin
Drug Market: Regional Segmentation
On the basis of region, the market has been segmented into
North America, South America, Asia Pacific (APAC), Europe, and the Middle East
& Africa (MEA). North America represents the largest market for
Erythropoietin. This growth can be partly attributed to rising cancer
prevalence and increased incidence of renal diseases in the U.S. and Canada.
Other factors that favour the market growth in the region include widespread
accessibility of cutting-edge medical services and strong government support.
North America is followed by Europe and APAC respectively. The market is likely
to witness towering gains in APAC in particular. In addition, the APAC
erythropoietin drug market is projected to exhibit the fastest growth during
the forecast period. Increased penetration of healthcare services and expanding
patient population in countries such as China and India. Moreover, increased
government effort to improve healthcare in these countries is creating further
opportunities. LatAm and the MEA regions hold relatively lower share of the
global erythropoietin drug market.
Competitive
Landscape
Amgen (US), Teva Pharmaceutical Industries Ltd. (Israel),
Emcure Pharmaceuticals (India), Hospira (US), LG Life Sciences Ltd. (Korea),
Kyowa Hakko Kirin, Boehringer Ingelheim (US), Intas Pharmaceuticals (India),
Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Celltrion, Inc.
(South Korea), 3SBio, Biocon (India), BIOSIDUS (Argentina), and Dahua
Pharmaceutical (China).
- Reportedly, well before
any other country, China approves a new anaemia drug “Roxadustat” from
FibroGen and AstraZeneca. Roxadustat supports a novel oral anaemia
treatment known as hypoxia-inducible factor prolyl hydroxylase inhibitor.
The drug is viewed as a convenient alternative to erythropoietin or EPO.
- AstraZeneca has recently
partnered with UK-based artificial intelligence specialist BenevolentAI.
The partnership will allow AstraZeneca to leverage machine learning and AI
for drug discovery projects focusing on idiopathic pulmonary fibrosis
(IPF) and chronic kidney disease (CKD).
Related Report-
https://community.tccwpg.com/read-blog/173958
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5The Floor, New York,
New York 10013
Comments
Post a Comment